Literature DB >> 1828264

Binding of IgG containing immune complexes to human neutrophil Fc gamma RII and Fc gamma RIII induces actin polymerization by a pertussis toxin-insensitive transduction pathway.

P J Brennan1, S H Zigmond, A D Schreiber, E R Smith, F S Southwick.   

Abstract

The ability of a phagocytic stimulus, rabbit IgG anti-BSA/BSA immune complexes, to increase the F-actin content of human polymorphonuclear leukocytes was quantitated by flow cytometry following staining with nitrobenzoxadiazole-phallacidin. A significant rise in F-actin assembly was induced by addition of 5 micrograms/ml immune complex. Concentrations of immune complex of more than 200 micrograms/ml caused a maximal (approximately twofold) increase in F-actin content. After a delay of 5 s, the F-actin levels rose and reached maximum levels by 60 s after adding immune complexes. The twofold elevation in F-actin persisted for up to 60 min. Both anti-Fc gamma RII and anti-Fc gamma RIII mAb blocked immune complex stimulated actin polymerization. Exposure to pertussis toxin failed to affect the rate or extent of immune complex-induced actin polymerization. Cells incubated with immune complexes and then lysed with Triton had an increased number of sites able to nucleate actin polymerization. These findings suggest that immune complex binding to both polymorphonuclear leukocytes Fc gamma RII and Fc gamma RIII is required for actin filament assembly and that the induction of assembly occurs via transduction pathways that differ from those used by chemoattractants. As with adhesion this phagocytic stimulus induces actin assembly by a pertussis toxin insensitive pathway and produces a rise in actin filament content that persists for prolonged periods of time.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828264

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Polymerization of actin in RBL-2H3 cells can be triggered through either the IgE receptor or the adenosine receptor but different signaling pathways are used.

Authors:  J R Apgar
Journal:  Mol Biol Cell       Date:  1994-03       Impact factor: 4.138

2.  No association between neutrophil FcgammaRIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis.

Authors:  W Y Tse; S Abadeh; A McTiernan; R Jefferis; C O Savage; D Adu
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

3.  Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis.

Authors:  W Y Tse; S Abadeh; R Jefferis; C O Savage; D Adu
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

4.  On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.

Authors:  P W Parren; P A Warmerdam; L C Boeije; J Arts; N A Westerdaal; A Vlug; P J Capel; L A Aarden; J G van de Winkel
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

5.  Critical but overlapping role of FcgammaRIII and FcgammaRIV in activation of murine neutrophils by immobilized immune complexes.

Authors:  Zoltán Jakus; Tamás Németh; J Sjef Verbeek; Attila Mócsai
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

6.  Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases.

Authors:  Hiroshi Nishi; Kazuhiro Furuhashi; Xavier Cullere; Gurpanna Saggu; Mark J Miller; Yunfeng Chen; Florencia Rosetti; Samantha L Hamilton; Lihua Yang; Spencer P Pittman; Jiexi Liao; Jan M Herter; Jeffrey C Berry; Daniel J DeAngelo; Cheng Zhu; George C Tsokos; Tanya N Mayadas
Journal:  J Clin Invest       Date:  2017-09-11       Impact factor: 14.808

7.  Relationship of F-actin distribution to development of polar shape in human polymorphonuclear neutrophils.

Authors:  T D Coates; R G Watts; R Hartman; T H Howard
Journal:  J Cell Biol       Date:  1992-05       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.